O	0	3	The
O	4	11	effects
O	12	14	of
B-intervention	15	18	low
I-intervention	18	19	-
I-intervention	19	27	thrombin
I-intervention	28	34	fibrin
I-intervention	35	42	sealant
O	43	45	on
B-condition	46	51	wound
I-condition	52	58	serous
I-condition	59	67	drainage
I-condition	67	68	,
I-condition	69	75	seroma
I-condition	76	85	formation
I-condition	86	89	and
I-condition	90	96	length
I-condition	97	99	of
I-condition	100	113	postoperative
I-condition	114	118	stay
O	119	121	in
O	122	130	patients
O	131	141	undergoing
O	142	150	axillary
O	151	155	node
O	156	166	dissection
O	167	170	for
O	171	177	breast
O	178	184	cancer
O	184	185	.

O	186	187	A
O	188	198	randomized
O	199	209	controlled
O	210	215	trial
O	215	216	.

O	217	223	Breast
O	224	230	cancer
O	231	238	surgery
O	239	243	with
O	244	252	axillary
O	253	268	lymphadenectomy
O	269	272	may
O	273	275	be
O	276	286	associated
O	287	291	with
O	292	301	prolonged
O	302	306	stay
O	307	309	of
O	310	313	the
O	314	319	drain
O	320	322	in
O	323	326	the
O	327	333	axilla
O	334	337	due
O	338	340	to
O	341	345	high
O	346	351	wound
O	352	358	output
O	358	359	,
O	360	365	which
O	366	369	may
O	370	377	require
O	378	385	further
O	386	396	treatments
O	397	400	and
O	401	408	prolong
O	409	412	the
O	413	419	length
O	420	422	of
O	423	427	stay
O	427	428	,
O	429	438	impairing
O	439	446	quality
O	447	449	of
O	450	454	life
O	454	455	.

O	456	458	No
O	459	469	definitive
O	470	474	data
O	475	478	are
O	479	488	available
O	489	499	concerning
O	500	503	how
O	504	506	to
O	507	514	prevent
O	515	519	this
O	520	532	complication
O	532	533	.

O	534	537	Our
O	538	541	aim
O	542	545	was
O	546	548	to
O	549	555	assess
O	556	559	the
O	560	568	efficacy
O	569	571	of
O	572	573	a
O	574	577	new
O	578	581	low
O	581	582	-
O	582	590	thrombin
O	591	597	fibrin
O	598	602	glue
O	603	605	in
O	606	614	reducing
O	615	618	the
O	619	625	serous
O	626	632	output
O	633	637	from
O	638	641	the
O	642	650	axillary
O	651	659	surgical
O	660	665	wound
O	666	668	in
B-eligibility	669	677	patients
I-eligibility	678	688	undergoing
I-eligibility	689	697	axillary
I-eligibility	698	702	node
I-eligibility	703	713	dissection
I-eligibility	714	717	for
I-eligibility	718	724	breast
I-eligibility	725	731	cancer
O	731	732	,
O	733	736	and
O	737	740	its
O	741	745	long
O	745	746	-
O	746	750	term
O	751	758	effects
O	759	761	on
O	762	772	lymphedema
O	772	773	.

B-total-participants	774	779	Sixty
O	780	788	patients
O	789	799	undergoing
O	800	807	surgery
O	808	815	between
O	816	825	September
O	826	830	2012
O	831	834	and
O	835	839	June
O	840	844	2013
O	845	849	were
O	850	858	enrolled
O	858	859	.

B-intervention-participants	860	866	Thirty
O	867	875	patients
O	876	884	received
O	885	891	Artiss
O	891	892	®
O	892	893	(
O	893	899	Baxter
O	899	900	,
O	901	903	UK
O	903	904	)
O	905	911	fibrin
O	912	916	glue
O	917	921	plus
O	922	930	drainage
O	930	931	,
O	932	935	and
B-control-participants	936	938	30
B-control	939	947	drainage
I-control	948	953	alone
O	953	954	.

O	955	956	A
O	957	969	multivariate
O	970	978	analysis
O	979	982	was
O	983	992	performed
O	993	995	to
O	996	1004	identify
O	1005	1015	predictors
O	1016	1018	of
O	1019	1025	seroma
O	1025	1026	,
O	1027	1030	and
O	1031	1039	subgroup
O	1040	1048	analyses
O	1049	1053	were
O	1054	1063	performed
O	1063	1064	.

O	1065	1075	Lymphedema
O	1076	1079	was
O	1080	1088	assessed
O	1089	1091	12
O	1092	1098	months
O	1099	1104	after
O	1105	1112	surgery
O	1112	1113	.

O	1114	1122	Patients
O	1123	1126	who
O	1127	1135	received
O	1136	1142	fibrin
O	1143	1147	glue
O	1148	1151	had
O	1152	1159	reduced
B-outcome	1160	1165	serum
I-outcome	1166	1172	output
O	1173	1182	collected
O	1183	1185	in
O	1186	1189	the
O	1190	1195	drain
O	1196	1201	after
O	1202	1209	surgery
O	1210	1211	(
B-iv-cont-mean	1211	1213	94
I-iv-cont-mean	1213	1214	.
I-iv-cont-mean	1214	1215	3
O	1216	1217	±
B-iv-cont-sd	1218	1220	22
I-iv-cont-sd	1220	1221	.
I-iv-cont-sd	1221	1222	4
O	1223	1225	vs
B-cv-cont-mean	1226	1229	176
O	1230	1231	±
B-cv-cont-sd	1232	1234	24
I-cv-cont-sd	1234	1235	.
I-cv-cont-sd	1235	1236	6
I-cv-cont-sd	1237	1239	ml
O	1240	1241	p
O	1242	1243	<
O	1244	1245	0
O	1245	1246	.
O	1246	1249	001
O	1249	1250	)
O	1251	1254	and
O	1255	1262	shorter
B-outcome	1263	1269	length
I-outcome	1270	1272	of
I-outcome	1273	1286	postoperative
I-outcome	1287	1295	hospital
I-outcome	1296	1300	stay
O	1301	1302	(
O	1302	1303	p
O	1304	1305	=
O	1306	1307	0
O	1307	1308	.
O	1308	1311	001
O	1311	1312	)
O	1312	1313	.

B-outcome	1314	1323	Incidence
I-outcome	1324	1326	of
I-outcome	1327	1333	seroma
O	1334	1336	at
O	1337	1338	4
O	1338	1339	-
O	1339	1343	week
O	1344	1350	follow
O	1350	1351	-
O	1351	1353	up
O	1354	1357	did
O	1358	1361	not
O	1362	1368	differ
O	1369	1376	between
O	1377	1383	groups
O	1383	1384	.

O	1385	1387	At
O	1388	1400	multivariate
O	1401	1409	analysis
O	1409	1410	,
O	1411	1414	BMI
O	1415	1416	≥
O	1417	1419	30
O	1420	1422	kg
O	1422	1423	/
O	1423	1424	m
O	1424	1425	(
O	1425	1426	2
O	1426	1427	)
O	1428	1431	was
O	1432	1435	the
O	1436	1440	only
O	1441	1452	independent
B-outcome	1453	1462	predictor
I-outcome	1463	1465	of
I-outcome	1466	1472	seroma
I-outcome	1473	1482	formation
O	1483	1484	(
O	1484	1486	OR
O	1487	1488	=
O	1489	1490	2
O	1490	1491	.
O	1491	1492	7
O	1492	1493	,
O	1494	1496	95
O	1496	1497	%
O	1497	1499	CI
O	1500	1501	1
O	1501	1502	.
O	1502	1503	4
O	1503	1504	-
O	1504	1505	5
O	1505	1506	.
O	1506	1507	3
O	1507	1508	;
O	1509	1510	p
O	1511	1512	=
O	1513	1514	0
O	1514	1515	.
O	1515	1518	002
O	1518	1519	)
O	1519	1520	.

O	1521	1531	Overweight
O	1532	1540	patients
O	1541	1550	receiving
O	1551	1557	Artiss
O	1557	1558	®
O	1559	1562	had
O	1563	1568	fewer
B-outcome	1569	1575	seroma
O	1576	1578	at
O	1579	1580	4
O	1580	1581	-
O	1581	1585	week
O	1586	1592	follow
O	1592	1593	-
O	1593	1595	up
O	1596	1604	compared
O	1605	1609	with
O	1610	1617	control
O	1618	1628	overweight
O	1629	1637	patients
O	1638	1639	(
B-iv-bin-percent	1639	1640	0
I-iv-bin-percent	1640	1641	%
O	1642	1644	vs
B-cv-bin-percent	1645	1647	55
I-cv-bin-percent	1647	1648	.
I-cv-bin-percent	1648	1649	6
I-cv-bin-percent	1649	1650	%
O	1650	1651	,
O	1652	1653	p
O	1654	1655	=
O	1656	1657	0
O	1657	1658	.
O	1658	1660	03
O	1660	1661	)
O	1661	1662	.

O	1663	1665	No
O	1666	1677	differences
O	1678	1682	were
O	1683	1691	observed
O	1692	1694	in
B-outcome	1695	1705	lymphedema
O	1706	1713	between
O	1714	1720	groups
O	1721	1722	(
B-iv-bin-percent	1722	1723	6
I-iv-bin-percent	1723	1724	.
I-iv-bin-percent	1724	1725	7
I-iv-bin-percent	1725	1726	%
O	1727	1729	vs
B-cv-bin-percent	1730	1732	10
I-cv-bin-percent	1732	1733	%
O	1733	1734	,
O	1735	1736	p
O	1737	1738	>
O	1739	1740	0
O	1740	1741	.
O	1741	1743	99
O	1743	1744	)
O	1744	1745	.

O	1746	1749	Low
O	1749	1750	-
O	1750	1758	thrombin
O	1759	1765	fibrin
O	1766	1770	glue
O	1771	1778	reduced
O	1779	1782	the
B-outcome	1783	1789	amount
I-outcome	1790	1792	of
I-outcome	1793	1798	fluid
O	1799	1807	produced
O	1808	1810	in
O	1811	1814	the
O	1815	1821	axilla
O	1822	1827	after
O	1828	1834	breast
O	1835	1842	surgery
O	1842	1843	.

O	1844	1854	Overweight
O	1855	1863	patients
O	1864	1867	may
O	1868	1870	be
O	1871	1874	the
O	1875	1880	ideal
O	1881	1891	candidates
O	1892	1895	for
O	1896	1900	this
O	1901	1910	treatment
O	1910	1911	.

O	1912	1916	Such
O	1917	1924	sealant
O	1925	1928	did
O	1929	1932	not
O	1933	1941	increase
O	1942	1945	the
O	1946	1951	rates
O	1952	1954	of
O	1955	1965	lymphedema
O	1965	1966	.
